 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
PK/PD data, Journal: Effect of E7777 Immunogenicity on Pharmacokinetics, Efficacy, and Safety in Adult Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma. (Pubmed Central) - Feb 26, 2025
Serious TE adverse events were reported by 32.1% of TE E-ADA-positive patients, 29.0% of TE I-ADA-positive patients, 100% of E-ADA-negative patients, and 73.3% of I-ADA-negative patients. These results indicate that the presence of ADAs decreased E7777 exposure over time but did not adversely impact efficacy and safety in patients with CTCL.
- | Kymriah (tisagenlecleucel-T) / Novartis, Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
Trial completion date, Trial primary completion date: Study of E7777 Prior to Kymriah for R/R DLBCL (clinicaltrials.gov) - Jan 9, 2025
P1/2, N=30, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
These results indicate that the presence of ADAs decreased E7777 exposure over time but did not adversely impact efficacy and safety in patients with CTCL. Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
- | Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology, Ontak (denileukin diftitox) / Eisai, TSD Japan
Journal: Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma. (Pubmed Central) - Dec 19, 2024
Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025 Efficacy and safety results show that DD-cxdl would potentially fulfill a serious, unmet medical need for patients with R/R CTCL.
- Keytruda (pembrolizumab) / Merck (MSD), Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
T-regulatory cell depletion with E7777 combined with pembrolizumab in patients with recurrent solid tumors: phase I trial (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_416;
Initial efficacy data are encouraging including patients who progressed on prior anti-PD1 therapy. Ongoing translational work is ongoing to explore the impact on level of T-regulatory cells and CD8 T-cells and if it correlates with clinical benefit.
- ||||||| Lymphir (denileukin diftitox-cxdl) / Citius, Eisai
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study) (clinicaltrials.gov) - Dec 11, 2023
P=N/A, N=118, Completed, Sponsor: Eisai Inc.
Ongoing translational work is ongoing to explore the impact on level of T-regulatory cells and CD8 T-cells and if it correlates with clinical benefit. Recruiting --> Completed | N=85 --> 118 | Trial completion date: Nov 2026 --> Mar 2023 | Trial primary completion date: Nov 2026 --> Mar 2023
- | Lymphir (denileukin diftitox-cxdl) / Citius, Eisai
Preclinical, Journal: Targeting regulatory T cells by E7777 enhances CD8 T-cell-mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models. (Pubmed Central) - Dec 3, 2023
Treatment with E7777 was safe and well-tolerated. Combined E7777 and anti-PD-1 therapy was well tolerated and more effective than monotherapy with either drug.
- I/ONTAK (denileukin diftitox purified) / Citius, Eisai
Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302 (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_4307;
P3
There is no evidence of cumulative toxicity. Most patients had at least 1 TEAE which were mostly Grade 1/2.
- I/ONTAK (denileukin diftitox purified) / Citius, Eisai
Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302 (ENMCC - 393-396) - Nov 4, 2022 - Abstract #ASH2022ASH_3653;
P3
The ORR of 36.2% per IRC (42.3% by investigator assessment) showed that a substantial proportion of these heavily pretreated patients experienced clinical benefit after E7777 treatment similar to ONTAK. The observed tumor responses were rapid, durable, and deep.
- ||| Keytruda (pembrolizumab) / Merck (MSD), Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
Enrollment open, Checkpoint inhibition: HCC 21-166: T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors (clinicaltrials.gov) - Oct 5, 2022
P1/2, N=70, Recruiting, Sponsor: Haider Mahdi
The observed tumor responses were rapid, durable, and deep. Not yet recruiting --> Recruiting
- | I/ONTAK (denileukin diftitox purified) / Citius, Eisai
Preclinical, Journal: Preclinical and clinical researches of Denileukin Diftitox (Genetical Recombination) (Remitoro), a novel agent for T-cell lymphoma (Pubmed Central) - Sep 10, 2022
Therefore, safety monitoring activities have been continued along with alerting related events. Based on these results, E7777 obtained a new drug approval in Japan in March 2021 for the indication of relapsed or refractory PTCL/CTCL.
- || Keytruda (pembrolizumab) / Merck (MSD), Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
Trial initiation date, Checkpoint inhibition: HCC 21-166: T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors (clinicaltrials.gov) - Jul 13, 2022
P1/2, N=70, Not yet recruiting, Sponsor: Haider Mahdi
Based on these results, E7777 obtained a new drug approval in Japan in March 2021 for the indication of relapsed or refractory PTCL/CTCL. Initiation date: Mar 2022 --> Jul 2022
- || Keytruda (pembrolizumab) / Merck (MSD), Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
Trial completion date, Trial primary completion date, Checkpoint inhibition: HCC 21-166: T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors (clinicaltrials.gov) - Mar 28, 2022
P1/2, N=70, Not yet recruiting, Sponsor: Haider Mahdi
Initiation date: Mar 2022 --> Jul 2022 Trial completion date: Jan 2027 --> Dec 2027 | Trial primary completion date: Jan 2025 --> Dec 2025
- Opdivo (nivolumab) / Ono Pharma, BMS
MECHANISMS OF T CELL TOLERANCE AFTER PT-CY HAPLOTRANSPLANTATION (North Hall / Virtual Hall 6) - Jan 30, 2022 - Abstract #EBMT2022EBMT_924;
We found Treg, Tr1 activity, or T-cell exhaustion to be insignificant as their removal or blocking antibodies did not lead to ‘flare’ in T-cell reactivity against patient DC. T-cell clonal deletion appears to be the dominant mechanism explaining the in vitro hyporeactive proliferation, cytokine secretion, and alloreactive TCR clonotype attrition.
- |||| Keytruda (pembrolizumab) / Merck (MSD), Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
New P1/2 trial, Checkpoint inhibition: HCC 21-166: T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors (clinicaltrials.gov) - Jan 19, 2022
P1/2, N=70, Not yet recruiting, Sponsor: Haider Mahdi
- ||||| Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
Trial completion: study-302: A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma (clinicaltrials.gov) - Jan 18, 2022
P3, N=115, Completed, Sponsor: Eisai Inc.
T-cell clonal deletion appears to be the dominant mechanism explaining the in vitro hyporeactive proliferation, cytokine secretion, and alloreactive TCR clonotype attrition. Active, not recruiting --> Completed
- Opdivo (nivolumab) / Ono Pharma, BMS, I/ONTAK (denileukin diftitox purified) / Citius, Eisai
Mechanisms of T Cell Tolerance after Ptcy Haplotransplantation (Salt Palace Convention Center Ballroom J) - Dec 3, 2021 - Abstract #TCTASTCTCIBMTR2022TCT_ASTCT_CIBMTR_372;
All received Flu+TBI (+/- Cy) pre-conditioning and haplo-HSCT with post-transplant Cytoxan (PTCy) and FK506 as GvHD prophylaxis...To test the involvement of Tregs, we depleted them from purified T cells with Denileukin Diftitox (IL2R immunotoxin, Seragen Inc™) pre-incubation...T-cell exhaustion was tested by blocking the PD1 pathway with anti-PD1 MoAb (OPDIVO, Bristol Myers Squibb™)...T-cell clonal deletion appears to be the dominant mechanism explaining the in vitro hyporeactive proliferation, cytokine secretion, and alloreactive TCR clonotype attrition. Anergy may play a minor supportive role.
- |||||| Lymphir (denileukin diftitox-cxdl) / Citius, Eisai
New trial: A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study) (clinicaltrials.gov) - Nov 29, 2021
P=N/A, N=85, Recruiting, Sponsor: Eisai Inc.
- ||| Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
Trial completion date, Trial primary completion date: study-302: A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma (clinicaltrials.gov) - Oct 15, 2021
P3, N=115, Active, not recruiting, Sponsor: Eisai Inc.
Anergy may play a minor supportive role. Trial completion date: Sep 2021 --> Feb 2022 | Trial primary completion date: Sep 2021 --> Feb 2022
- |||| Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
Enrollment closed: study-302: A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma (clinicaltrials.gov) - Aug 16, 2021
P3, N=115, Active, not recruiting, Sponsor: Eisai Inc.
Trial completion date: Sep 2021 --> Feb 2022 | Trial primary completion date: Sep 2021 --> Feb 2022 Recruiting --> Active, not recruiting
- | Kymriah (tisagenlecleucel-T) / Novartis, Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
Enrollment open: Study of E7777 Prior to Kymriah for R/R DLBCL (clinicaltrials.gov) - Jul 14, 2021
P1/2, N=30, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Kymriah (tisagenlecleucel-T) / Novartis, Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
New P1/2 trial: Study of E7777 Prior to Kymriah for R/R DLBCL (clinicaltrials.gov) - Apr 22, 2021
P1/2, N=30, Not yet recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
- ||| Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
Trial completion date, Trial primary completion date: study-302: A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma (clinicaltrials.gov) - Oct 9, 2020
P3, N=115, Recruiting, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting Trial completion date: Mar 2021 --> Aug 2021 | Trial primary completion date: Mar 2021 --> Aug 2021
- ||| Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
Trial completion date, Trial primary completion date: study-302: A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma (clinicaltrials.gov) - May 14, 2020
P3, N=115, Recruiting, Sponsor: Eisai Inc.
Trial completion date: Mar 2021 --> Aug 2021 | Trial primary completion date: Mar 2021 --> Aug 2021 Trial completion date: Apr 2020 --> Mar 2021 | Trial primary completion date: Mar 2020 --> Mar 2021
- |||| Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
Enrollment open: study-302: A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma (clinicaltrials.gov) - Feb 5, 2020
P3, N=115, Recruiting, Sponsor: Eisai Inc.
Trial completion date: Apr 2020 --> Mar 2021 | Trial primary completion date: Mar 2020 --> Mar 2021 Active, not recruiting --> Recruiting
- ||||| Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
Enrollment change: study-302: A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma (clinicaltrials.gov) - Dec 12, 2019
P3, N=115, Active, not recruiting, Sponsor: Eisai Inc.
Active, not recruiting --> Recruiting N=70 --> 115
- || Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
Trial completion: Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma (clinicaltrials.gov) - Nov 10, 2019
P2, N=37, Completed, Sponsor: Eisai Co., Ltd.
N=70 --> 115 Active, not recruiting --> Completed
- | Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
Trial completion date, Trial primary completion date: study-302: A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma (clinicaltrials.gov) - Oct 16, 2019
P3, N=70, Active, not recruiting, Sponsor: Eisai Inc.
Active, not recruiting --> Completed Trial completion date: Dec 2019 --> Mar 2020 | Trial primary completion date: Dec 2019 --> Mar 2020
- | Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
Enrollment closed: study-302: A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma (clinicaltrials.gov) - Sep 30, 2019
P3, N=70, Active, not recruiting, Sponsor: Eisai Inc.
Trial completion date: Dec 2019 --> Mar 2020 | Trial primary completion date: Dec 2019 --> Mar 2020 Recruiting --> Active, not recruiting
- ||| Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
Trial completion date, Trial primary completion date: study-302: A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma (clinicaltrials.gov) - Apr 22, 2019
P3, N=70, Recruiting, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting Trial completion date: Jun 2019 --> Dec 2019 | Trial primary completion date: Jun 2019 --> Dec 2019
- | Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
Enrollment closed: Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma (clinicaltrials.gov) - Nov 29, 2018
P2, N=35, Active, not recruiting, Sponsor: Eisai Co., Ltd.
Trial completion date: Jun 2019 --> Dec 2019 | Trial primary completion date: Jun 2019 --> Dec 2019 Recruiting --> Active, not recruiting
- | Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
Trial completion date, Trial primary completion date: Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma (clinicaltrials.gov) - Sep 28, 2018
P2, N=35, Recruiting, Sponsor: Eisai Co., Ltd.
Recruiting --> Active, not recruiting Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2018 --> Jun 2019
- | Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
Enrollment change, Trial primary completion date: study-302: A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma (clinicaltrials.gov) - Aug 22, 2018
P3, N=56, Recruiting, Sponsor: Eisai Inc.
Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2018 --> Jun 2019 N=90 --> 56 | Trial primary completion date: Mar 2019 --> Jun 2019
- | Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
Trial primary completion date: Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma (clinicaltrials.gov) - May 31, 2018
P2, N=35, Recruiting, Sponsor: Eisai Co., Ltd.
N=90 --> 56 | Trial primary completion date: Mar 2019 --> Jun 2019 Trial primary completion date: Sep 2018 --> Dec 2018
- |||| Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
Trial primary completion date: study-302: A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma (clinicaltrials.gov) - Sep 13, 2017
P3, N=90, Recruiting, Sponsor: Eisai Inc.
Trial primary completion date: Sep 2018 --> Dec 2018 Trial primary completion date: Jun 2019 --> Mar 2019
- |||||| Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
Enrollment open, Enrollment change, Trial initiation date, Trial primary completion date: study-302: A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma (clinicaltrials.gov) - Aug 12, 2016
P3, N=90, Recruiting, Sponsor: Eisai Inc.
Trial primary completion date: Jun 2019 --> Mar 2019 N=21 --> 90 | Initiation date: May 2013 --> May 2016 | Trial primary completion date: Sep 2016 --> Jun 2019 | Active, not recruiting --> Recruiting
- | Lymphir (denileukin diftitox-cxdl) / Citius, Eisai
Enrollment open: Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma (clinicaltrials.gov) - Apr 1, 2016
P2, N=35, Recruiting, Sponsor: Eisai Co., Ltd.
N=21 --> 90 | Initiation date: May 2013 --> May 2016 | Trial primary completion date: Sep 2016 --> Jun 2019 | Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Lymphir (denileukin diftitox-cxdl) / Citius, Eisai
Trial completion: E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma (clinicaltrials.gov) - Feb 8, 2016
P1, N=13, Completed, Sponsor: Eisai Co., Ltd.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Lymphir (denileukin diftitox-cxdl) / Citius, Eisai
New P2 trial: Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma (clinicaltrials.gov) - Feb 8, 2016
P2, N=35, Not yet recruiting, Sponsor: Eisai Co., Ltd.
- | Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
Enrollment change: study-302: A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma (clinicaltrials.gov) - Jan 28, 2016
P3, N=21, Active, not recruiting, Sponsor: Eisai Inc.
Active, not recruiting --> Completed N=90 --> 21
- Lymphir (denileukin diftitox-cxdl) / Citius, Eisai
Enrollment change, Trial primary completion date: E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma (clinicaltrials.gov) - Jun 6, 2015
P1, N=13, Active, not recruiting, Sponsor: Eisai Co., Ltd.
N=90 --> 21 N=24 --> 13 | Trial primary completion date: Mar 2015 --> Aug 2015
- Lymphir (denileukin diftitox-cxdl) / Citius, Eisai
Enrollment closed: E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma (clinicaltrials.gov) - Mar 12, 2015
P1, N=24, Active, not recruiting, Sponsor: Eisai Co., Ltd.
N=24 --> 13 | Trial primary completion date: Mar 2015 --> Aug 2015 Recruiting --> Active, not recruiting
- ||||| Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
Enrollment closed: study-302: A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma (clinicaltrials.gov) - Jan 22, 2015
P3, N=90, Active, not recruiting, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Lymphir (denileukin diftitox-cxdl) / Citius, Eisai
Trial primary completion date: E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma (clinicaltrials.gov) - Dec 17, 2014
P1, N=24, Recruiting, Sponsor: Eisai Co., Ltd.
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2014 --> Mar 2015
- |||| Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
Trial primary completion date: study-302: A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma (clinicaltrials.gov) - Jul 30, 2014
P3, N=90, Recruiting, Sponsor: Eisai Inc.
Trial primary completion date: Sep 2014 --> Mar 2015 Trial primary completion date: Jun 2016 --> Sep 2016
- Lymphir (denileukin diftitox-cxdl) / Citius, Eisai
Enrollment change: E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma (clinicaltrials.gov) - Jan 21, 2014
P1, N=24, Recruiting, Sponsor: Eisai Co., Ltd.
Trial primary completion date: Jun 2016 --> Sep 2016 N=42 --> 24
- Lymphir (denileukin diftitox-cxdl) / Citius, Eisai
Trial withdrawal, Combination therapy: A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma (clinicaltrials.gov) - Nov 13, 2013
P3, N=0, Withdrawn, Sponsor: Eisai Inc.
N=42 --> 24 Terminated --> Withdrawn
- Lymphir (denileukin diftitox-cxdl) / Citius, Eisai
Enrollment change, Combination therapy: A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma (clinicaltrials.gov) - Nov 13, 2013
P3, N=0, Withdrawn, Sponsor: Eisai Inc.
Terminated --> Withdrawn N=352 --> 0
- |||||| Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
Enrollment open: study-302: A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma (clinicaltrials.gov) - Jul 14, 2013
P3, N=90, Recruiting, Sponsor: Eisai Inc.
N=352 --> 0 Active, not recruiting --> Recruiting
- |||||||||| Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
New P3 trial: study-302: A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma (clinicaltrials.gov) - Jun 5, 2013
P3, N=90, Recruiting, Sponsor: Eisai Inc.